Literature DB >> 22496457

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

Marta Palafox1, Irene Ferrer, Pasquale Pellegrini, Sergi Vila, Sara Hernandez-Ortega, Ander Urruticoechea, Fina Climent, Maria Teresa Soler, Purificación Muñoz, Francesc Viñals, Mark Tometsko, Dan Branstetter, William C Dougall, Eva González-Suárez.   

Abstract

Paracrine signaling through receptor activator of NF-κB (RANK) pathway mediates the expansion of mammary epithelia that occurs during pregnancy, and activation of RANK pathway promotes mammary tumorigenesis in mice. In this study we extend these previous data to human cells and show that the RANK pathway promotes the development of mammary stem cells and breast cancer. Overexpression of RANK (FL-RANK) in a panel of tumoral and normal human mammary cells induces the expression of breast cancer stem and basal/stem cell markers. High levels of RANK in untransformed MCF10A cells induce changes associated with both stemness and transformation, including mammary gland reconstitution, epithelial-mesenchymal transition (EMT), increased migration, and anchorage-independent growth. In addition, spheroids of RANK overexpressing MCF10A cells display disrupted acinar formation, impair growth arrest and polarization, and luminal filling. RANK overexpression in tumor cells with nonfunctional BRCA1 enhances invasiveness in acinar cultures and increases tumorigenesis and metastasis in immunodeficient mice. High levels of RANK were found in human primary breast adenocarcinomas that lack expression of the hormone receptors, estrogen and progesterone, and in tumors with high pathologic grade and proliferation index; high RANK/RANKL expression was significantly associated with metastatic tumors. Together, our findings show that RANK promotes tumor initiation, progression, and metastasis in human mammary epithelial cells by increasing the population of CD44(+)CD24(-) cells, inducing stemness and EMT. These results suggest that RANK expression in primary breast cancer associates with poor prognosis. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496457     DOI: 10.1158/0008-5472.CAN-12-0044

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

Review 1.  Reproduction and breast cancer risk.

Authors:  Volker Hanf; Dorothea Hanf
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

Review 2.  NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors:  K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal:  Cell Oncol (Dordr)       Date:  2015-08-29       Impact factor: 6.730

3.  Breast cancer likely to metastasise to bone if RANK expression high.

Authors: 
Journal:  Bonekey Rep       Date:  2012-06-20

4.  Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases.

Authors:  Leandro Marcelo Martinez; Valeria Beatriz Fernández Vallone; Vivian Labovsky; Hosoon Choi; Erica Leonor Hofer; Leonardo Feldman; Raúl Horacio Bordenave; Emilio Batagelj; Federico Dimase; Ana Rodriguez Villafañe; Norma Alejandra Chasseing
Journal:  Clin Exp Metastasis       Date:  2013-10-31       Impact factor: 5.150

5.  Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.

Authors:  Danja Sarink; Helena Schock; Theron Johnson; Kim Overvad; Marianne Holm; Anne Tjønneland; Marie-Christine Boutron-Ruault; Mathilde His; Marina Kvaskoff; Heiner Boeing; Pagona Lagiou; Eleni-Maria Papatesta; Antonia Trichopoulou; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Carlotta Sacerdote; H B As Bueno-de-Mesquita; Carla H van Gils; Petra H Peeters; Elisabete Weiderpass; Antonio Agudo; Maria-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; Kay Tee Khaw; Ruth Travis; Laure Dossus; Mark Gunter; Sabina Rinaldi; Melissa Merritt; Elio Riboli; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Prev Res (Phila)       Date:  2017-07-12

6.  RANKL inhibitors for osteosarcoma treatment: hope and caution.

Authors:  Eva M Trinidad; Eva González-Suárez
Journal:  Ann Transl Med       Date:  2016-12

7.  RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.

Authors:  Chaido Sirinian; Anastasios D Papanastasiou; Michail Schizas; Magda Spella; Georgios T Stathopoulos; Maria Repanti; Ioannis K Zarkadis; Tari A King; Haralabos P Kalofonos
Journal:  Oncogene       Date:  2018-05-29       Impact factor: 9.867

Review 8.  Breast cancer stem cells and the immune system: promotion, evasion and therapy.

Authors:  Sarah T Boyle; Marina Kochetkova
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-07-06       Impact factor: 2.673

9.  Impact of progesterone on stem/progenitor cells in the human breast.

Authors:  Heidi N Hilton; Christine L Clarke
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-08-08       Impact factor: 2.673

Review 10.  Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.

Authors:  Cathrin Brisken
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.